LAMP1 and neoplasm: Immunostaining of the lysosomal marker LAMP1 was performed on tumor sections from short-term refametinib-treated mouse PDAC tumors equally showed an overexpression of the LAMP1 gene product upon MEKi treatment (Fig. 1c).